You are here: Industry Insights > Opdivo-Yervoy

News List

Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial nasdaq
November 28, 2018
Bristol-Myers Squibb Company BMYannounced that the phase III CheckMate-451 study on immuno-oncology drug Opdivo in combination with Yervoy was unsuccessful....
Bristol-Myers reports positive results for Opdivo-Yervoy combination for advanced melanoma pharmaceutical-technology
October 23, 2018
Bristol-Myers Squibb has announced positive results from its trial into the efficacy of combination therapy with Opdivo (nivolumab) and Yervoy (ipilimumab), compared with either drug as a monotherapy, for patients with advanced melanoma.
Korea approves Opdivo-Yervoy for renal cell carcinoma treatment biospectrumasia
September 29, 2018
The approval is based on a clinical trial called CheckMate-214.
Bristol-Myers' Opdivo-Yervoy cocktail slashes kidney cancer death risk by 37% fiercepharma
September 11, 2017
MADRID, Spain—Bristol-Myers Squibb smashed doubt about Opdivo and Yervoy’s utility in first-line kidney cancer on Sunday with data showing patients lived longer when treated up front with the combo,